Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PTN | P21246 | 1/20 | 0.40 |
| ▸ | MDK | P21741 | 1/20 | 0.40 |
| ▸ | BDNF | P23560 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CD69 | Q07108 | 1/20 | 0.37 |
| ▸ | HK1 | P19367 | 1/20 | 0.37 |
| ▸ | HK2 | P52789 | 1/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17689074 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL22362645 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL15966272 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL30089326 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL15966248 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL23631128 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL15965653 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| Phosphoric Acid SCHEMBL27756060 | 0.95 | AMDHD2 (0.46) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL20415021 | 0.88 | BDNF (0.38) | MAPK1ALDH1A1THRBPTNMDK | |
| SCHEMBL16566075 | 0.87 | ALDH1A1 (0.40) | MAPK1ALDH1A1THRBPTNMDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119375384-A | Method for in-vitro detection of mucopolysaccharide and pompe disease related biomarker | 浙江博圣生物技术股份有限公司 | 2025-01-28 | — | — | CN | claimed |
| EP-3060669-B1 | AAV-5 PSEUDOTYPED VECTOR FOR GENE THERAPY FOR NEUROLOGICAL DISEASES | UNIQURE IP BV (NL) | 2024-12-11 | — | — | EP | claimed |
| WO-2023229403-A1 | YDJC INHIBITOR SCREENING METHOD | 동국대학교 산학협력단 | 2023-11-30 | — | — | WO | claimed |
| EP-3782639-B1 | COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES | REGENERON PHARMA (US) | 2022-07-20 | — | — | EP | claimed |
| EP-3256594-B1 | ENHANCED DELIVERY OF VIRAL PARTICLES TO THE STRIATUM AND CORTEX | GENZYME CORP (US) | 2021-10-20 | — | — | EP | claimed |
| US-12636307-B2 | In vitro heparin and heparan sulfate compositions and methods of making and using | TEGA THERAPEUTICS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260042998-A1 | Glyco-Engineered Yeast for Therapeutic Protein Production | VIB VZW (BE) | 2026-02-12 | — | — | US | disclosed |
| EP-4578462-A2 | DERMAL FILLER COMPOSITIONS | ALLERGAN Industrie, SAS (FR) | 2025-07-02 | — | — | EP | disclosed |
| EP-4570825-A2 | THE IN VIVO USE OF CHONDROITINASE AND/OR HYALURONIDASE TO ENHANCE DELIVERY OF AN AGENT | Inovio Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20250179211-A1 | Antibodies and antibody fragments and analogues specific for chondroitin sulfate | VAR2 PHARMACEUTICALS APS (DK) | 2025-06-05 | — | — | US | disclosed |
| US-20250154476-A1 | IMPROVED HEPARAN SULFATE AND METHODS OF MAKING THE SAME | UNIVERSITY OF COPENHAGEN (DK) | 2025-05-15 | — | — | US | disclosed |
| EP-3448993-B1 | THE IN VIVO USE OF CHONDROITINASE AND/OR HYALURONIDASE TO ENHANCE DELIVERY OF AN AGENT | INOVIO PHARMACEUTICALS INC (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-110542728-B | Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI and VII | 华盛顿大学商业中心 | 2022-05-24 | — | — | CN | disclosed |
| US-20220142948-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-05-12 | — | — | US | disclosed |
| EP-3969014-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | ExThera Medical Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220023186-A1 | DERMAL FILLER COMPOSITIONS | ALLERGAN INDUSTRIE, SAS (FR) | 2022-01-27 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-10286045-B2 | Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof | KINETIQ, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180236048-A1 | SUBCUTANEOUS THERAPEUTIC ENZYME FORMULATIONS, USES, AND METHODS FOR GENERATING THEREOF | KINETIQ THERAPEUTICS, LLC | 2018-08-23 | — | — | US | disclosed |
| CN-105899154-A | Injection device for minimally invasive surgical procedures and applications thereof | 全球生物疗法有限公司 | 2016-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023186-A1 | DERMAL FILLER COMPOSITIONS | CD44, HACD3, CUTA | MAPK1 4233/4885AMDHD2 58/4885ALDH1A1 822/4885 |
| US-12636307-B2 | In vitro heparin and heparan sulfate compositions and methods of making and using | TPST2, CSGALNACT1, B4GALT1 | MAPK1 2095/4885AMDHD2 268/4885ALDH1A1 2044/4885 |
| US-20260042998-A1 | Glyco-Engineered Yeast for Therapeutic Protein Production | MAN2A1, OGA, ERG28 | MAPK1 612/4885AMDHD2 324/4885ALDH1A1 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.